Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass

Model scores of the 29,894 trials active now.

Model score 35% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (381 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cardiac surgerybypassthe safetydetermined byas determined
  Phrases that lowered it: patientstrialpatientlunggiven
• Sponsor's past termination rate: 15% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Blinding: triple (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Maximum age: 0.42 (raises risk) · Who can join
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Minimum age: not given (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design
• Keywords listed: 0 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 17 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children? NCT01780584 · started 2010 · scored riskier than 50% of active trials completed
• Oral Triiodothyronine for Infants Less Than 5 Months & Malnourished Children Undergoing Cardiopulmonary Bypass in Indonesia NCT02222532 · started 2013 · scored riskier than 42% of active trials completed
• Oral Triiodothyronine for Children Undergoing Cardiopulmonary Bypass in Indonesia NCT02521168 · started 2013 · scored riskier than 47% of active trials completed
• L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects NCT02891837 · started 2016 · scored riskier than 23% of active trials completed
• Antithrombin III in Infants With Cardiopulmonary Bypass (CPB) NCT01698567 · started 2012 · scored riskier than 57% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.